Eagles Face Uncertain Future With Hurts Sidelined by Blood Clots

The Philadelphia Eagles face a pivotal decision regarding quarterback Jalen Hurts following his diagnosis of blood clots that will keep him sidelined for the 2026 season. The injury removes the immediate performance concerns that have surrounded the quarterback and shifts the narrative to financial and strategic considerations for the franchise.

Hurts' contract situation provides the Eagles with considerable flexibility in determining their path forward. With only $22 million guaranteed for 2027, the team can pursue several options without significant financial penalty. These include extending the quarterback to signal long-term commitment, trading him to another franchise, releasing him outright, or retaining him for the upcoming season after his recovery.

Each option carries distinct implications for the Eagles' competitive timeline and salary cap management. An extension would signal confidence in Hurts as the franchise quarterback, while a trade could yield draft capital or players in return. A release would free up resources but potentially waste the investment already made in developing the player.

The franchise must weigh Hurts' performance in previous seasons, his health trajectory, and the availability of alternative quarterback solutions in the market. The upcoming months will be critical as the Eagles gather medical information and assess their roster needs before making a formal decision on the quarterback's future with the organisation.

Photo: Jalen Hurts of the Philadelphia Eagles against the Washington Commanders at Lincoln Financial Field, Philadelphia, November 2022. All-Pro Reels via Wikimedia Commons (CC BY-SA 2.0).